|
|
|
 |
 |
|
|
Guy-Charles has over 15 years of experience in biotechnology.
Prior to joining Neovacs, Guy-Charles was Vice-President,
member of the Executive Committee and General Manager for
Europe for IDM. He led the European operations, a fully integrated
unit from Basic Research to Business Development with 70 employees.
Before that, Guy-Charles spent 8 years with Biogen, where
he founded the French and Benelux commercial operations, moved
to the USA to become National Director of Sales ($675m) and
where his last position was Vice-President of Strategic Commercial
Operations, responsible for the Regulatory, Medical and Marketing
Operations for the International Unit. From 1990 to 1995,
Guy-Charles worked at Schering-Plough in various positions
including International Product Manager for Intron A (a recombinant
interferon a) based in the US and Cytokine Business Unit Manager
in France. In 1989, Guy-Charles gained sales experience at
Baxter after having started his career in the industry at
Boehringer Ingelheim within the Animal Health department.
Guy-Charles holds a Doctorate in Veterinary Medicine from
the Ecole Nationale Veterinaire de Lyon (France) and an MBA
from INSEAD (Fontainebleau, France).
|
| |
 |
| |
Bernard is in charge of leading the Pharmaceutical Development
activities at Neovacs. He brings more than 30 years of industrial
experience in vaccine pharmaceutical development. Bernard
was previously Senior Vice President, Pharmaceutical Development,
of Flamel Technologies. Prior to Flamel, Bernard was Corporate
Vice President, Global Industrialization, at Sanofi Pasteur.
Bernard holds a degree in biological chemistry from the University
of Lyon, France.
|
| |
 |
| |
Pierre brings more than 20 years of experience in clinical development, including 18 in the field of vaccines, both prophylactic and therapeutic.
Prior to Neovacs, Pierre was most recently Director of Clinical Research and Early Development at GlaxoSmithKline Biologicals, in charge of the clinical evaluation of early phase projects, new formulations and adjuvants.
Pierre has also been involved in the development of major vaccines like combined pediatric vaccines, Hepatitis A and B vaccines, Prophylactic Herpes Simplex, Therapeutic Hepatitis B and C, HPV and HSV vaccines and also HIV Prophylactic and Therapeutic vaccines, Tuberculosis, Chlamydia trachomatis and adult Streptococcus pneumoniae vaccines.
Prior to GSK Biologicals, Pierre had worked at ICI Pharmaceuticals from 1987 to 1990, working on cardio-vascular products.
Pierre holds a Medical Doctorate from the Universities of Namur and Louvain-Brussels, a Postgraduate Diploma in Tropical Medicine from the Institute of Tropical Medicine of Antwerp and a PhD in Biomedical Medicine from the University of Ghent.
|
| |
 |
|
|
Olivier is in charge of Pharmaceutical development (CMC) and Quality Assurance/ GMP compliance. CMC activities include management of the lab process and analytical development activities as well as the interface with contract manufacturing or test organizations for technology transfer, development and GMP manufacturing of clinical batches. Olivier is also one of the project leaders for the overall development of Neovacs’ vaccine candidates. Olivier has 9 years of experience in immune therapy development and cell-based vaccine manufacturing. He previously held positions at Anosys - a US/French cell therapy biotech company – and research activities for 7 years at Gustave Roussy Institute (molecular biology and genomics) and Pasteur Institute where he was a post-doctorate fellow in molecular pharmacology. He had previously spent 4 years as a resident in several hospital departments (pediatry, pharmacology and biochemistry). Olivier holds a Degree in Pharmacy (Paris XI University, France) and a PhD in Virology (Pierre et Marie Curie University, France).
|
|
 |
|
Géraldine is in charge of R&D new targets and brings
6 years of R&D experience in the US. She was previously
working at Sanofi-Pasteur USA in bacterial vaccine development.
Before this industrial experience she was working at the Walter
Reed Army Institute of Research on Dengue vaccine development
and in Seattle University studying HIV-dendritic cells interactions.
Géraldine holds a Degree in Pharmacy from Angers University
(France) and did her PhD in Immunology with Dr Jacques Banchereau
at Schering-Plough Lyon (France). She has authored several
scientific publications in peer-reviewed journals.
|
 |
|
|
|
